SKF 38393 and SCH 23390 inhibit reuptake of serotonin by rat hypothalamic synaptosomes

Pharmacology

Volumn 87, Issue 1-2, 2011, Pages 85-89

  Zarrindast, M R ^a   Honardar, Z ^b   Sanea, F ^b   Owji, A A ^b,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Reuptake; SCH 23390; Serotonin; SKF 38393

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; CLOMIPRAMINE; DESIPRAMINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG UPTAKE; HYPOTHALAMUS; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; SYNAPTOSOME;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ANTIDEPRESSIVE AGENTS; BENZAZEPINES; HYPOTHALAMUS; MALE; OSMOLAR CONCENTRATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPTOSOMES;

EID: 78651395450     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323232     Document Type: Article

References (46)

1. Waddington JL, O'Boyle KM: Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D-1 antagonist. Pharmacol Ther 1989; 43: 1-52. (Pubitemid 19199086)
2. 1 receptor ligands: where are we now and where are we going. Med Res Rev 2009; 29: 272-294.
3. Arnt J, Hyttel J: Behavioral differentiation between effects elicited at dopamine D-1 and D-2 receptors in rats with normosensitive DA receptors. Pharmacopsychiatry 1988; 21: 24-27. (Pubitemid 18073877)
4. 1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur J Pharmacol 1992; 213: 259-267.
5. Desai RI, Terry P, Katz JL: Comparison of the discriminative-stimulus effects of SKF 38393 with those of other dopamine receptor agonists. Behav Pharmacol 2003; 14: 223-228. (Pubitemid 36735155)
6. 1 dopaminergic antagonists and agonists in mice and squirrel monkeys. J Pharmacol Exp Ther 1999; 291: 265-279. (Pubitemid 29451599)
7. 1 agonists in squirrel monkeys. Psychopharmacology (Berl) 2001; 157: 208-216. (Pubitemid 32802135)
8. Briggs CA, Pollock NJ, Frail DE, Paxson CL, Rakowski RF, Kang CH, Kebabian JW: Activation of the 5-HT 1C receptor expressed in Xenopus oocytes by the benzazepines SCH 23390 and SKF 38393. Br J Pharmacol 1991; 104: 1038-1044.
9. Zarrindast MR, Owji AA, Hosseini-Nia T: Evaluation of dopamine receptor involvement in rat feeding behaviour. Gen Pharmacol 1991; 22: 1011-1016.
10. 1 antagonists and 5-HT 1A agonists. J Pharmacol Exp Ther 1995; 273: 101-112.
11. Bischoff S, Heinrich M, Sonntag JM, Krauss J: The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT 2 ) receptors. Eur J Pharmacol 1986; 129: 367-370. (Pubitemid 16008034)
12. 1Csites in pig choroid plexus. Eur J Pharmacol 1988; 150: 181-184.
13. Woodward RM, Panicker MM, Miledi R: Actions of dopamine and dopaminergic drugs on cloned serotonin receptors expressed in Xenopus oocytes. Proc Natl Acad Sci USA 1992; 89: 4708-4712.
14. 1receptor blockade. Neuropsychopharmacology 2005; 30: 2180-2191. (Pubitemid 41643969)
15. Hicks PE, Schoemaker H, Langer SZ: 5HTreceptor antagonist properties of SCH 23390 in vascular smooth muscle and brain. Eur J Pharmacol 1984; 105: 339-342. (Pubitemid 14024449)
16. Tomiyama K, Koshikawa N, Funada K, Oka K, Kobayashi M: In vivo microdialysis evidence for transient dopamine release by benzazepines in rat striatum. J Neurochem 1995; 65: 2790-2795.
17. Saigusa T, Aono Y, Sekino R, Uchida T, Takada K, Oi Y, Koshikawa N, Cools AR: Contribution of vesicular and cytosolic dopamine to the increased striatal dopamine efflux elicited by intrastriatal injection of SKF 38393. Eur J Pharmacol 2009; 624: 10-15.
18. 2 dopamine receptors. Neuroscience 1986; 19: 125-137. (Pubitemid 16053634)
19. Pfeiffer FR, Wilson JW, Weinstock J, Kuo GY, Chambers PA, Holden KG, Hahn RA, Wardell JR Jr, Tobia AJ, Setler PE, Sarau HM: Dopaminergic activity of substituted 6-chloro- 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines. J Med Chem 1982; 25: 352-358. (Pubitemid 12078634)
20. 3 H]SCH 23390 binding to human putamen D-1 dopamine receptors: stereochemical and structure- affinity relationships among 1-phenyl- 1H-3-benzazepine derivatives as a guide to D-1 receptor topography. J Neurochem 1987; 48: 1039-1042. (Pubitemid 18001323)
21. Spencer PS: Review of the pharmacology of existing antidepressants. Br J Clin Pharmacol 1977; 4(suppl 2):57S-68S. (Pubitemid 8184497)
22. Kannengiesser MH, Hunt PF, Raynaud JP: Comparative action of fenfluramine on the uptake and release of serotonin and dopamine. Eur J Pharmacol 1976; 35: 35-43.
23. Roman DL, Walline CC, Rodriguez GJ, Barker EL: Interactions of antidepressants with the serotonin transporter: a contemporary molecular analysis. Eur J Pharmacol 2003; 479: 53-63. (Pubitemid 37377875)
24. Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE: Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007; 67: 27-55. (Pubitemid 46105086)
25. Adan RA, Vanderschuren LJ, la Fleur SE: Anti- obesity drugs and neural circuits of feeding. Trends Pharmacol Sci 2008; 29: 208-217.
26. Drago A, Serretti A: Focus on HTR 2C : a possible suggestion for genetic studies of complex disorders. Am J Med Genet B Neuropsychiatr Genet 2009; 150B:601-637.
27. Gorwood P: Eating disorders, serotonin transporter polymorphisms and potential treatment response. Am J Pharmacogenomics 2004; 4: 9-17. (Pubitemid 38325701)
28. Tecott LH, Abdallah L: Mouse genetic approaches to feeding regulation: serotonin 5-HT 2C receptor mutant mice. CNS Spectr 2003; 8: 584-588.
29. Crespi D, Mennini T, Gobbi M: Carrierdependent and Ca 2+ -dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4- methylendioxymethamphetamine, p -chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 1997; 121: 1735-1743.
30. 2002; 297: 609-611. (Pubitemid 34815346)
31. Breisch ST, Zemlan FP, Hoebel BG: Hyperphagia and obesity following serotonin depletion by intraventricular p -chlorophenylalanine. Science 1976; 192: 382-385.
32. Booth RF, Clark JB: A rapid method for the preparation of relatively pure metabolically competent synaptosomes from rat brain. Biochem J 1978; 176: 365-370. (Pubitemid 9061168)
33. 3H] noradrenaline in homogenates from rat hypothalamus. Biochem Pharmacol 1979; 28: 1085-1088. (Pubitemid 9186513)
34. Bolden-Watson C, Richelson E: Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023-1029.
35. Thomas DR, Nelson DR, Johnson AM: Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 1987; 93: 193-200. (Pubitemid 18013056)
36. Riblet LA, Gatewood CF, Mayol RF: Comparative effects of trazodone and tricyclic antidepressants on uptake of selected neurotransmitters by isolated rat brain synaptosomes. Psychopharmacology (Berl) 1979; 63: 99-101. (Pubitemid 9232847)
37. Sugrue MF: Antagonism of fenfluramineinduced hyperthermia in rats by some, but not all, selective inhibitors of 5-hydroxytryptamine uptake. Br J Pharmacol 1984; 81: 651-657. (Pubitemid 14148374)
38. Placheta P, Singer E, Kriwanek W, Hertting G: Mepiprazole, a new psychotropic drug: effects on uptake and retention of monoamines in rat brain synaptosomes. Psychopharmacology (Berl) 1976; 48: 295-301.
39. Lenox RH, Frazer A: Mechanism of action of antidepressants and mood-stabilizers; in Davis KL (ed): Neuropsychopharmacology. The Fifth Generation of Progress. Baltimore, Lippincott Williams & Willkins, 2002.
40. Terry P, Gilbert DB, Cooper SJ: Dopamine receptor subtype agonists and feeding behavior. Obes Res 1995; 3(suppl 4):515S-523S.
41. 1 -like receptor agonists on foodmaintained operant behavior in rats. Behav Pharmacol 2006; 17: 303-309. (Pubitemid 44258978)
42. Katz JL, Witkin JM: Behavioral effects of dopaminergic agonists and antagonists alone and in combination in the squirrel monkey. Psychopharmacology (Berl) 1993; 113: 19-25. (Pubitemid 23341040)
43. Habuchi Y, Tanaka H, Nishio M, Yamamoto T, Komori T, Morikawa J, Yoshimura M: Dopamine stimulation of cardiac β -adrenoceptors: the involvement of sympathetic amine transporters and the effect of SKF38393. Br J Pharmacol 1997; 122: 1669-1678. (Pubitemid 28000195)
44. 3H]SCH 23390. Brain Res 1986; 375: 291-301. (Pubitemid 16078046)
45. 1 dopamine receptor activity of antiparkinsonian drugs. Life Sci 1997; 60: 1597-1603. (Pubitemid 27186423)
46. 1 receptor enhances inositol phosphates formation in rat brain. J Pharmacol Exp Ther 1990; 253: 987-992. (Pubitemid 20209354)